[1] Giovanella L, D'Aurizio F, Algeciras-Schimnich A, et al. Thyroglobulin and thyroglobulin antibody: an updated clinical and laboratory expert consensus [J]. Eur J Endocrinol, 2023, 189(2): R11-R27. DOI: 10.1093/ejendo/lvad109.
[2] Hao Y, Zhong L. Feasibility study on individualized management of postoperative patients with differentiated thyroid cancer based on internet and programming technology [J]. J Cancer Res Clin Oncol, 2023, 149(13): 12405-12412. DOI: 10.1007/s00432-023-05078-2.
[3] Sonavane SN, Upadhye T, Basu S. Sellar-parasellar and petrous bone metastasis from differentiated thyroid carcinoma: imaging characteristics and follow-up profile post radioiodine therapy [J]. World J Nucl Med, 2023, 22(2): 144-149. DOI: 10.1055/s-0043-1768664.
[4] VDP. Influence of hypothyroidism on the variability of carotenoid coloration in amatitlania nigrofasciata females (Cichlidae) [J]. J Ichthyol, 2023, 63(6): 1188-1194.
[5] 朱国华,邹贤,王国瑞,等. 持续/复发分化型甲状腺癌二次手术生存的影响因素[J]. 中国肿瘤外科杂志,2020,12(6):571-575. DOI:10.3969/j.issn.1674-4136.2020.06.018.
[6] 中华医学会内分泌学分会,中华医学会外科学分会甲状腺及代谢外科学组,中国抗癌协会头颈肿瘤专业委员会,等. 甲状腺结节和分化型甲状腺癌诊治指南(第二版)[J]. 中华内分泌代谢杂志,2023,39(3):181-226. DOI:10.3760/cma.j.cn311282-20221023-00589.
[7] Kalshetty A, Basu S. Assessment of pulmonary metastasis in differentiated thyroid carcinoma: value of HRCT correlation with functional imaging [J]. World J Nucl Med, 2023, 22(2): 87-99. DOI: 10.1055/s-0043-1764307.
[8] 王俊起. 分化型甲状腺癌的诊疗进展[J]. 实用医学杂志,2019,35(20):3258-3263. DOI:10.3969/j.issn.1006-5725. 2019.20.030.
[9] Zanocco K, Kaltman DJ, Wu JX, et al. Cost effectiveness of routine laryngoscopy in the surgical treatment of differentiated thyroid cancer [J]. Ann Surg Oncol, 2018, 25(4): 949-956. DOI: 10.1245/s10434-018-6356-2.
[10] Demir AN, Kara Z, Sulu C, et al. The effect of radioiodine therapy on blood cell count in patients with differentiated thyroid cancer [J]. Hormones (Athens), 2023, 22(4): 595-602. DOI: 10.1007/s42000-023-00479-x.
[11] Fabio V, Leandra P. The combined evaluation of clinical and biochemical data in management of patients with differentiated thyroid cancer [J]. Eur J Nucl Med Mol Imaging, 2023, 51(1): 230-232.
[12] Mosteiro L, Nguyen TTT, Hankeova S, et al. Notch signaling in thyrocytes is essential for adult thyroid function and mammalian homeostasis [J]. Nat Metab, 2023, 5(12): 2094-2110. DOI: 10.1038/s42255-023- 00937-1.
[13] 李婉萍,王昱锦,张婵,等. 血浆一氧化碳水平与甲状腺功能减退的关系及高压氧结合罗伊适应模式护理的治疗效果分析[J]. 中华航海医学与高气压医学杂志,2023,30(5):651-655. DOI:10.3760/cma.j.cn311847-20230508- 00114.
[14] Liu L, Zeng B, Zhang J, et al. Impact of subclinical hypothyroidism on in-hospital outcomes and long-term mortality among acute myocardial infarction patients with diabetic mellitus [J]. Acta Cardiol, 2024, 79(6): 650-658. DOI: 10.1080/00015385.2023.2279421.
[15] 张君宜,伍学焱. 甲状腺功能减退症与认知功能损伤的相关性[J]. 中华医学杂志,2023,103(5):378-382. DOI:10.3760/cma.j.cn112137-20220905-01875.
[16] 刘鹏飞,朱旭强,董阳,等. 原发性甲状腺功能减退致垂体增生的临床特点及治疗(附15例报道)[J]. 中华神经外科杂志,2023,39(8):804-807. DOI: 10.3760/cma.j.cn112050- 20221126-00553.
[17] 虞萌,黄家恺,冯飞,等. 老年2型糖尿病患者甲状腺功能减退发生影响因素[J]. 中国老年学杂志,2022,42(20):4946-4949. DOI:10.3969/j.issn.1005-9202.2022.20.014.
[18] 王瑞莲,谭锦云,卢梓荣,等. 鼻咽癌患者经调强放疗序贯抗PD-1免疫治疗后甲状腺功能减退的影响因素[J]. 实用医学杂志,2021,37(16):2114-2118. DOI: 10.3969/j.issn. 1006-5725.2021.16.016.
[19] 周凌,陈佳,黄爽,等. 鼻咽癌放射性甲状腺功能减退的相关因素研究[J]. 中华放射肿瘤学杂志,2021,30(1):11-15. DOI:10.3760/cma.j.cn113030-20200122-00030.
[20] 吴小颖,陈彤华,邢雪凤,等. HbA1c、E2、C肽对围绝经期、绝经后2型糖尿病患者合并亚临床甲状腺功能减退症的诊断价值[J]. 中国现代医学杂志,2023,33(1):24-31. DOI:10.3969/j.issn.1005-8982.2023.01.005.
[21] 周凌,陈佳,陶嫦娟,等. 鼻咽癌放射性甲状腺功能减退的研究进展[J]. 中华放射肿瘤学杂志,2021,30(5):523-526. DOI:10.3760/cma.j.cn113030-20200715-00367.
[22] 张君宜,伍学焱. 甲状腺功能减退症与认知功能损伤的相关性[J]. 中华医学杂志,2023,103(5):378-382. DOI:10.3760/cma.j.cn112137-20220905-01875.
[23] 魏晋红,路潇,胡鑫鑫,等. 左旋甲状腺素治疗亚临床甲状腺功能减退症和心血管疾病的研究现状[J]. 中国临床药理学杂志,2022,38(14):1696-1700. DOI:10.13699/j.cnki. 1001-6821.2022.14.027.
|